Growth Differentiation Factor 11 Is a Circulating Factor That Reverses Age-Related Cardiac Hypertrophy

Loffredo et al


In an intriguing new study, Loffredo et al report that joining the circulation of old mice with that of young mice reduces age-related cardiac hypertrophy. They also found that the growth factor growth/differentiation factor 11 is a circulating negative regulator of cardiac hypertrophy which suggests that raising growth/differentiation factor 11 levels may be useful to treat cardiac hypertrophy associated with aging.

As the human population ages, heart failure is increasing in prevalence.1 In heart failure, cardiac hypertrophy is associated with aging and is common in diastolic heart failure in which relaxation and filling is impaired.2–4 In a recent article in Cell, Loffredo et al5 demonstrate that age-related cardiac hypertrophy and increase in cardiomyocyte area in old mice can be reversed by surgically joining their circulatory system to that of young mice for 4 weeks. The expression of genes involved in hypertrophy in old mice were also altered by exposure to young blood. To identify candidate regulators of hypertrophy, the authors performed proteomic analysis of plasma from young and old mice and found that the levels of 13 proteins differentiate old versus young plasma. Then they show that 1 protein, growth/differentiation factor 11 (GDF11), a secreted growth factor and member of the transforming growth factor-β (TGF-β) superfamily, declines with age in mice. Daily injection of GDF11 into old mice mimicked the effects of exposure to young serum on aged hearts. GDF11 had no effect, however, on pressure overload-induced hypertrophy. These results suggest that increasing the circulating levels of GDF11 could potentially treat or prevent age-related cardiac hypertrophy.

The mechanisms by which cells age and lose their functional or regenerative capacity are of growing research interest spurred by the aging population. Some potential mechanisms of cellular aging include telomere shortening, oxidative damage, somatic mutations, and epigenetic changes. However, accumulating evidence suggests that the extracellular environment also changes with aging pointing to potentially new targets more amenable for therapeutics to improve or prevent age-related cellular decline.

In this study, an old technique is used to address questions about the environment of young or old cells. Prompted by the realization that conjoined twin pairs could share circulation, an experimental technique called parabiosis was developed to surgically pair 2 animals by joining the skin from the left flank of one to the right flank of the other, sometimes together with abdominal wall musculature.6 In the first description of this technique by Paul Bert in 1862,6 fluids administered to 1 rat were detectable in the parabiont which demonstrated that the circulatory systems were shared. When healthy and affected animals are paired, the technique allows the researcher to test whether a circulatory factor from one animal can change some feature of a tissue of interest in the other. Parabiosis has been used frequently since the early 20th century for a variety of investigations, but recently parabiosis has been used to demonstrate that circulatory factors differ between young and old animals.7 For example, the replication of hepatocytes,8 β-cells,9 skeletal muscle stem cells,8 and neuronal progenitors10 in old mice are increased by exposure to youthful circulation.

Loffredo et al5 use parabiosis to determine whether a specific type of cardiac hypertrophy related to aging is because of age-related differences in levels of a factor or factors in the blood. Previous studies have shown that left ventricular hypertrophy is associated with aging.2–4 Diastolic heart failure, heart failure with preserved ejection fraction, occurs in ≈50% of patients with heart failure.2–4 Diastolic heart failure is not associated with ventricular dilation, unlike systolic heart failure, which is heart failure with reduced ejection fraction. Most diastolic heart failure patients have ventricular and/or atrial hypertrophy and impaired relaxation and filling.2–4 Patients with diastolic heart failure are likely to be older, female, and hypertensive.1 Recent estimates indicate that the prevalence of diastolic heart failure is rising most likely due to an aging population.4

Loffredo et al5 generated parabiotic pairs of young with old (heterochronic) mice and compared their cardiac size with parabiotic pairs of mice of the same age (isochronic) and age-matched controls that did not undergo parabiosis. After 4 weeks only, cardiac hypertrophy was reversed in old heterochronically paired mice (Figure A). Heart weight (relative to tibia length) and cardiac myocyte area were decreased in old mice that were paired with young mice. Consistent with the altered morphometric phenotype, the expression of markers of cardiomyocyte hypertrophy was reduced while the expression of sarcoplasmic/endoplasmic reticulum calcium ATPase...
GDF11 is expressed widely during development and in adult muscle. To determine whether the effects of GDF11 on cardiac hypertrophy could be direct, the α1-adrenergic receptor agonist phenylephrine was used to promote hypertrophy of neonatal cardiomyocytes in vitro. Previous work has shown that α1-adrenergic receptors are involved in pathological cardiac responses including hypertrophy. The authors found that phenylephrine-induced hypertrophy was inhibited by the addition of GDF11 in vitro. This result suggests that GDF11 in circulation directly affects cardiac myocytes and is consistent with its role in preventing excess hypertrophy. An effect of GDF11 on expression of hypertrophic markers or sarcoplasmic/endoplasmic reticulum calcium ATPase 2 on cardiac myocytes in vitro was not attempted.

The function of GDF11 in cardiac muscle described by Loffredo et al is analogous to that of another TGF-β superfamily member, myostatin (MSTN), also known as GDF8 (Figure B). MSTN is a negative regulator of skeletal muscle hypertrophy, as demonstrated by a dramatic increase in skeletal muscle mass in a variety of animals and people with loss of function mutations. In addition, blocking postnatal MSTN signaling causes skeletal muscle fiber hypertrophy in mice. Consequently, a variety of MSTN or receptor inhibitors are in clinical trials for muscle wasting diseases, including sarcopenia, the age-related loss of muscle mass and strength. Nevertheless, it is unclear whether MSTN levels in muscle change with aging. However, sarcopenia seems to proceed at the same rate in MSTN null mice compared with wild-type mice, suggesting that MSTN does not regulate age-induced muscle loss at least in mice.

At the molecular level, GDF11 and MSTN are similar. GDF11 is 90% identical by amino acid sequence to MSTN. Each of these proteins is secreted in latent complex that needs to be proteolytically processed to release the receptor binding form of the molecule. These proteins are also inhibited by the same secreted proteins and bind to the same receptors. These similarities raise the issue of whether these factors are functionally redundant with each other in cardiac or skeletal...
muscle. In other words, can GDF11 inhibit skeletal muscle growth or can MSTN inhibit cardiac muscle growth? These questions are important because levels of these factors need to be manipulated in opposite directions to treat cardiac hypertrophy or skeletal muscle wasting. In addition, clinical trials of anti-MSTN therapies have already commenced. In fact, administration of certain inhibitors that neutralize several TGF-β family members causes further increases in skeletal muscle mass in MSTN knockout mice. These results clearly demonstrate that, in addition to MSTN, other TGF-β family members may be involved in regulating skeletal muscle growth.

A few studies have examined the redundancy between GDF11 and MSTN. Mice that are null for both genes have more severe axial skeletal defects than GDF11 single knockout mice, suggesting that the factors might be functionally redundant for anterior/posterior patterning during development. Similarly, administration of ectopic GDF11 or MSTN inhibits myogenesis in developing chick limb muscle and mouse C2C12 myoblast cultures. On the contrary, GDF11 deletion specifically in skeletal muscle does not cause skeletal muscle hypertrophy in wild-type or MSTN null mice, possibly attributable to the availability of circulating GDF11 provided by other tissues. Thus, the factors seem to have the same function during early developmental patterning although a function for GDF11 in skeletal muscle has not been demonstrated in vivo.

Even if GDF11 is shown to inhibit skeletal muscle growth in vivo, a difference in sensitivity between GDF11 and MSTN may allow doses of GDF11 to be used that do not cause skeletal muscle atrophy. Although muscle mass in mice is very sensitive to MSTN inhibitors, it seems to require very high concentrations of injected MSTN to achieve a significant decrease in skeletal muscle mass in wild-type mice. The concentrations injected in these in vivo studies are >1 order of magnitude greater than the GDF11 concentration used by Loffredo et al to reduce cardiac mass in old mice. Although Loffredo et al did not analyze skeletal muscle size after GDF11 treatment, in future studies it will be necessary to analyze skeletal muscle mass in response to a systemic changes in GDF11.

In recent work, the role of MSTN in the heart has received considerable attention. However, there are conflicting reports regarding cardiac phenotype and function in MSTN knockout mice. Some researchers have found increased heart weight in knockout mice, although others have not. MSTN is expressed in the heart at much lower levels than in skeletal muscle. MSTN transcript or protein expression in the heart is increased by infarct, aortic restriction, volume overload, and exercise, and in cardiac hypertrophy caused by overexpression of Akt in cardiomyocytes. Heinke et al proposed that the main effect of MSTN produced by the heart is to decrease skeletal muscle mass. They used a model of heart failure associated with skeletal muscle wasting, a risk factor for increased morbidity and mortality. By analyzing cardiac-specific MSTN deletion or overexpression lines of mice, Heinke et al showed that this wasting was caused by MSTN produced by the heart rather than skeletal muscle. However, they and others have found that heart weight is reduced slightly in transgenic mouse lines overexpressing MSTN in cardiac muscle as would be expected if MSTN is redundant to GDF11 in the heart.

The latter result suggests that MSTN may have an indirect effect on cardiac myocytes. As shown by Loffredo et al and others, MSTN activates similar signal transduction pathways in cardiac myocytes in culture as it does in skeletal muscle. Loffredo et al demonstrated that, unlike GDF11, the recombinant mature MSTN peptide could not block phenylephrine-induced hypertrophy of rat neonatal cardiac myocytes, suggesting they are not redundant for this function. In contrast, Morissette et al showed that adenoviral expression of full-length MSTN in rat neonatal cardiac myocytes efficiently blocks phenylephrine-induced hypertrophy. Furthermore, they showed that phenylephrine-induced cardiac hypertrophy is greater in MSTN knockout male mice than in wild-type mice, consistent with a marked effect of MSTN in inhibiting hypertrophy caused by α1-adrenergic stimulation in cardiac myocytes. The differing results of these in vitro experiments may be because of differences in effective doses of MSTN or the sensitivity to GDF11 compared with MSTN in this particular assay. Taken together, the effects of overexpression or deletion of MSTN on cardiac size are consistent with its role as a negative regulator of cardiomyocyte growth, although perhaps a relatively minor one when compared with GDF11.

Some therapeutic strategies to increase muscle mass promiscuously inhibit multiple TGF-β superfamily members in addition to MSTN. For example, a soluble activin receptor type IIB binds several superfamily ligands, including MSTN, GDF11, and the activins, and yields a greater increase in muscle mass than more specific anti-MSTN inhibitors. Activin A has been shown to regulate skeletal muscle mass in vivo similar to MSTN. Unfortunately, the soluble receptor approach has caused side effects such as nosebleeds, and the clinical trials have been halted. Another approach is to block one of the receptors that mediates skeletal muscle hypertrophy by using anti-activin receptor type IIB antibodies. Whether this strategy would stimulate cardiac hypertrophy by blocking GDF11 signaling in the heart depends on whether GDF11 function in cardiac myocytes requires activin receptor type IIB or another receptor. Finally, neutralizing monoclonal antibodies against MSTN that do not bind to GDF11 are 1 way to avoid blocking the hypertrophic effect of GDF11 inhibition on cardiac myocytes.

In summary, this exciting study suggests new therapeutic options for the treatment for age-related cardiac hypertrophy. However, future preclinical and clinical studies that target GDF11 or MSTN must be carefully designed to avoid unwanted side effects in skeletal or cardiac muscle or the other tissues that produce or respond to GDF11. Avoidance of such side effects, even if subtle, may be particularly important in the treatment of diseases that require long-term treatment. An interesting remaining question is whether declining GDF11 levels in the blood affect other organs in aging animals, but this remains to be studied. Overall, this study by Loffredo et al provides additional evidence in support of the concept that the changes in the extracellular milieu can cause age-related dysfunction in a wide variety of organs. Elucidation of additional molecular differences in the circulating and local extracellular environments may yield more targets for antiaging therapies in the future.
Sources of Funding

Dr McPherron is supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

Disclosures

Under a licensing agreement between Pfizer and the Johns Hopkins University, Dr McPherron is entitled to a share of royalty received by the University on sales of myostatin and is also a co-inventor on a GDF11 patent. The terms of these arrangements are being managed by the University with accordance with its conflict of interest policies.

References


Through Thick and Thin: A Circulating Growth Factor Inhibits Age-Related Cardiac Hypertrophy
Alexandra C. McPherron

Circ Res. 2013;113:487-491
doi: 10.1161/CIRCRESAHA.113.302239

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/113/5/487

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/